National Institute of Cancerología Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT03296553
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

National Institute of Cancerología

Active Ingredients

Drugs in Phase 2 Trials (1)

valganciclovir (valcyte) (1 trial)

Drugs in Other Trials (1)

omega-3 fatty acids (omacor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

HIV Infections (Phase 2)

Immune Reconstitution Inflammatory Syndrome (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2